Delayed lymphocyte infusion in children given SCT

Bone Marrow Transplantation

Volumn 41, Issue SUPPL. 2, 2008, Pages

  Klingebiel, T ^a   Bader, P ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN A;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CANCER IMMUNOTHERAPY; CHILD; CHIMERA; CYTOTOXICITY; DELAYED LYMPHOCYTE INFUSION; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIESIS; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; LYMPHOCYTE DIFFERENTIATION; MINIMAL RESIDUAL DISEASE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; REMISSION; SHORT TANDEM REPEAT; STEM CELL TRANSPLANTATION; T LYMPHOCYTE ACTIVATION;

CHILD; DISEASE-FREE SURVIVAL; GRAFT REJECTION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE TRANSFUSION; STEM CELL TRANSPLANTATION; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS;

EID: 45749087817     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.49     Document Type: Article

References (18)

1. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990: 76: 2462-2465.
2. Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation, J Clin Oncol 1997; 15: 433-444.
3. Riddell SR, Murata M, Bryant S, Warren EH. T-cell therapy of leukemia. Cancer Control 2002; 9: 114-122.
4. Bader P, Holle W, Klingebiel T, Handgretinger R, Benda N, Schlegel PG et al. Mixed hematopoietic chimerism after allogeneic bone marrow transplantation: The impact of quantitative PCR analysis for prediction of relapse and graft rejection in children. Bone Marrow Transplant. 1997; 19: 697-702.
5. Bader P, Klingebiel T,. Schaudt A, Theurer-Mainka U, Handgretinger R, Lang P et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: A single center experience of 12 children. Leukemia 1999; 13: 2079-2086.
6. Bader P, Beck J, Schlegel PG, Handgretinger R, Niethammer D, Klingebiel T. Additional immunotherapy on the basis of increasing mixed hematopoietic chimerism after allogeneic BMT in children with acute leukemia: Is there an option to prevent relapse? Bone Marrow Transplant 1997; 20: 79-81.
7. Bader P, Kreyenberg H. Hoelle W, Dueckers G, Handgretinger R, Lang P et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: Possible role for pre-emptive immunotherapy? J Clin Oncol 2004; 22: 1696-1705.
8. Bader P. Niethammer D. Willasch A. Kreyenberg H. Klingebiel T. How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow Transplant 2005; 35: 107-119.
9. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Kremens B. Dilloo D et al. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective. Bone Marrow Transplant 2004; 33: 815-821.
10. Yoshimi A, Bader P, Matthes-Martin S, Stary J, Sedlacek P. Duffner U et al. Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia 2005; 19: 971-977.
11. Willasch A, Hoelle W. Kreyenberg H. Niethammer D. Handgretinger R, Lang P et al. Outcome of allogeneic stem cell transplantation in children with non-malignant diseases. Haematologica 2006: 91 788-794.
12. Hoelle W, Beck JF. Dueckers G, Krevenberg H. Lang P, Gruhn B et al Clinical relevance of serial quantitative analysis of hematopoietic chimerism after allogeneic stem cell transplantation in children for severe aplastic anemia. Bone Marrow Transplant 2004; 33: 219-223.
13. Krejci O, van der Velden VH, Bader P, Kreyenberg H. Goulden N, Hancock J et al. Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: A report of the Pre-BMT MRD Study Group. Bone Marrow Transplant 2003; 32: 849-851.
14. Goulden N, Bader P, Van Der Velden V, Moppett J, Schilham M. Masden HO et al. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukemia. Br J Haematol 2003; 122 24-29.
15. Bader P. Hancock J. Krevenberg H. Goulden NJ, Niethammer D. Oakhill A et al. Minimal residual disease (MRD) Status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 2002: 16: 1668-1672.
16. Szczepanski T. Why and how to quantity minimal residual disease in acute lymphoblastic leukemia? Leukemia 2007; 21: 622-626.
17. Schilham MW. Balduzzi A, Bader P. Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells? Bone Marrow Transplant 2005; 35: (Suppl 1): S49-S52.
18. Blair A, Goulden NJ, Libri NA, Oakhill A, Pamphilon DH. Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation. Blood Rev 2005: 19: 289-300.